Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer

Author:

O'Malley David M1ORCID,Myers Tashanna2,Wimberger Pauline3,Gorp Toon Van4,Redondo Andres5,Cibula David6,Nicum Shibani7,Rodrigues Manuel8,Backes Floor J1,Barlin Joyce N9,Lewin Sharyn N10,Lim Peter11,Pothuri Bhavana12,Diver Elisabeth13,Banerjee Susana14,Lorusso Domenica15

Affiliation:

1. Gynecologic Oncology, James Cancer Center/The Ohio State University, Columbus, OH 43210, USA

2. Obstetrics and Gynecology, UMass Chan Medical School, Springfield, MA 01199, USA

3. Gynecology and Obstetrics, and Gynecological Oncology, Carl Gustav Carus University, Technische Universität Dresden, Dresden, 01307, Germany

4. Division of Gynaecological Oncology, University Hospital Leuven, Leuven Cancer Institute, Leuven, BGOG, 3000, Belgium

5. Servicio de Oncología Médica, Hospital Universitario La Paz-IdiPAZ, Madrid, 28046, Spain

6. Department of Gynaecology, Obstetrics & Neonatology, General University Hospital in Prague & First Faculty of Medicine, Charles University, Prague, 120 00;110 00, Czech Republic

7. Oncology, University College London Hospitals NHS Foundation Trust, London, NW1 2BU, UK

8. Medical Oncology, Institut Curie., PSL Research University, INSERM U830, Paris, 75006, France

9. Women's Cancer Care Associates, Albany Medical College, Albany, NY 12208, USA

10. Gynecologic Oncology, Holy Name Medical Center, Teaneck, NJ 07666, USA

11. Center of Hope, University of Nevada, Reno School of Medicine, Reno, NV 89557, USA

12. Gynecologic Oncology, Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA

13. Medical Affairs, ImmunoGen, Inc., Waltham, MA 02451, USA

14. Gynaecology Unit, The Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, SW3 6JJ, UK

15. Gynaecological Oncology Unit, Catholic University of Rome & Fondazione Policlinico Gemelli IRCCS, Rome, 00168,Italy

Funder

ImmunoGen

Publisher

Informa UK Limited

Reference53 articles.

1. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer

2. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

3. Treatment of epithelial ovarian cancer

4. World Health Organization International Agency for Research on Cancer. Ovary. https://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf (Accessed December 1 2023).

5. Globocan 2020 Europe. International Agency for Research on Cancer. Lyon, France: World Health Organization; 2020. Fact Sheet 908.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3